Although the incidence of malnutrition did not differ significantly between patients treated with and without infliximab (42.3% vs. 51.7%, p = 0.235), those receiving infliximab had higher ALB levels (40.4 ± 0.7 vs. 37.9 ± 0.7, p = 0.016). This evidence concerns the gene ALB and nutritional deficiency disease.